KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $0.12.

  • Pacira BioSciences' EPS (Basic) rose 10385.85% to $0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.46, marking a year-over-year increase of 12335.03%. This contributed to the annual value of -$2.15 for FY2024, which is 33718.38% down from last year.
  • Per Pacira BioSciences' latest filing, its EPS (Basic) stood at $0.12 for Q3 2025, which was up 10385.85% from -$0.11 recorded in Q2 2025.
  • Pacira BioSciences' 5-year EPS (Basic) high stood at $0.56 for Q2 2023, and its period low was -$3.11 during Q3 2024.
  • For the 5-year period, Pacira BioSciences' EPS (Basic) averaged around $0.01, with its median value being $0.19 (2024).
  • As far as peak fluctuations go, Pacira BioSciences' EPS (Basic) soared by 125000.0% in 2023, and later crashed by 145217.39% in 2024.
  • Quarter analysis of 5 years shows Pacira BioSciences' EPS (Basic) stood at -$0.12 in 2021, then plummeted by 83.33% to -$0.22 in 2022, then skyrocketed by 344.57% to $0.54 in 2023, then crashed by 35.53% to $0.35 in 2024, then tumbled by 65.4% to $0.12 in 2025.
  • Its EPS (Basic) was $0.12 in Q3 2025, compared to -$0.11 in Q2 2025 and $0.1 in Q1 2025.